Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO
Diagnosoft, Inc., an innovator in magnetic resonance (MR) image analysis
software that assists in diagnosis, staging and therapeutic monitoring of
cardiovascular disease, has announced the closing of
financing led by Technology Development Fund (TDF) of
company intends to use the new capital to support further market expansion of
Diagnosoft(R) HARP(TM), Diagnosoft(R) PLUS, and Diagnosoft(R) SENC. The
capital infusion will also serve to further the development of other
innovative MR image analysis technologies designed to increase physician
productivity and accuracy, improve patient outcomes, and enhance research and
drug development advances.
“When cardiologists and radiologists can make a decision about the
condition of a patient’s heart based on quantitative data obtained from
cardiac MRI analysis, rather than just ‘eyeballing’ images,” said Diagnosoft
Co-Founder Dr.
substantiated, not subjective. When diagnosis and treatment is supported by
the numerical data our software provides, it’s stronger from a legal
standpoint as well.”
According to Dr.
Stuber at
the left ventricle of the heart — ECHO, nuclear medicine, CT, and so — but
we are focused on the emerging technology of MRI for the cardiac market. We
are kind of a one-stop shop for innovative analysis of the four magnetic
resonance imaging techniques — CINE, perfusion, delayed enhancement or
viability, and function or strain. Diagnosoft is the only company directly
looking at function, to see if the heart muscle is contracting properly;
consequently, we are the only ones who can put all four imaging techniques
together, and present it to the clinician in a single view.”
This unique capability made investment in Diagnosoft an attractive
endeavor for TDF. “It seems we are in the midst of a renaissance for
cardiovascular MRI. It’s amazing how much interest there is in the market
– it’s a very good time to be in the market, and we believe Diagnosoft is
clearly on the leading edge,” said
As Dr. Stuber explained, “As cardiovascular medicine grows, it is moving
away from being purely reactive — in other words, once you have an infarct,
you start treating it. I believe people with certain known risk factors will
undergo cardiovascular testing earlier. Quantitative analysis of myocardial
motion will be a crucial factor in being more proactive and informed in risk
assessment and early management for heart disease.”
To continue Diagnosoft’s commitment to cardiovascular imaging advances,
the company’s board of directors has appointed
CEO of Diagnosoft and a member of the board. With 20 years of healthcare
information technology experience, BenAchour will work closely with the
executive team to expand and solidify Diagnosoft’s position in the
marketplace. He started his career in business development, sales and
marketing, and quickly moved into executive management. His carrier spans
large, small as well as startup companies including HBOC and Per-Se
Technologies (both acquired by McKesson), CareFusion (acquired by Cardinal
Health), and CareSystems.
“I am delighted to be appointed president and CEO of Diagnosoft, and I am
very excited about the opportunities and the growth potential of our company,”
BenAchour said. “Since joining Diagnosoft, my principal focus has been to
establish our growth strategy for the benefit of our clients, employees and
investors. We are currently focusing on organizing our client services
efforts, establishing our sales and business development processes,
solidifying our brand and continuing to make improvement to the quality,
usability and reliability of our software solutions.”
About Diagnosoft
Diagnosoft, Inc., based in
held company specializing in image analysis software that assists in
diagnosis, staging and therapeutic monitoring of cardiovascular disease. One
of its products, Diagnosoft HARP(TM), is distinguished as the first FDA 510k-
cleared software designed for the analysis of tagged magnetic resonance
images. The company is focused on improving physician workflow, quantifying
decision-making, and enhancing research and drug development advances.
Company founders Dr.
technology at
Dr.
additional insight and imaging expertise to Diagnosoft. More information
about the company’s three MRI analysis software products, Diagnosoft(R)
HARP(TM), Diagnosoft(R) Plus and Diagnosoft(R) SENC, is available at
http://www.diagnosoft.com.
About Technology Development Fund
The Technology Development Fund, http://www.techdevfund.com, is the first
technology venture capital fund in the ME. Established in 2004, its current
capital base is
startup and early stage companies in the field of information technology. The
Fund is managed by one of the leading investment banks in the MENA region,
Efg-Hermes, http://www.efg-hermes.com, through its subsidiary Ideavelopers,
http://www.ideavelopers.com.
Diagnosoft(R) is a registered trademark of Diagnosoft, Inc. HARP(R) is a
registered trademark of
any proprietary interest in the marks and names of others.
Except for the historical information contained herein, this news release
contains forward-looking statements that involve risks and uncertainties.
Contact:
Firas BenAchour
1-919-388-9492
SOURCE Diagnosoft, Inc.